Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 197
Filtrar
1.
Am J Physiol Lung Cell Mol Physiol ; 310(11): L1088-97, 2016 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-27036867

RESUMO

The SU5416 + hypoxia (SuHx) rat model is a commonly used model of severe pulmonary arterial hypertension. While it is known that exposure to hypoxia can be replaced by another type of hit (e.g., ovalbumin sensitization) it is unknown whether abnormal pulmonary blood flow (PBF), which has long been known to invoke pathological changes in the pulmonary vasculature, can replace the hypoxic exposure. Here we studied if a combination of SU5416 administration combined with pneumonectomy (PNx), to induce abnormal PBF in the contralateral lung, is sufficient to induce severe pulmonary arterial hypertension (PAH) in rats. Sprague Dawley rats were subjected to SuPNx protocol (SU5416 + combined with left pneumonectomy) or standard SuHx protocol, and comparisons between models were made at week 2 and 6 postinitiation. Both SuHx and SuPNx models displayed extensive obliterative vascular remodeling leading to an increased right ventricular systolic pressure at week 6 Similar inflammatory response in the lung vasculature of both models was observed alongside increased endothelial cell proliferation and apoptosis. This study describes the SuPNx model, which features severe PAH at 6 wk and could serve as an alternative to the SuHx model. Our study, together with previous studies on experimental models of pulmonary hypertension, shows that the typical histopathological findings of PAH, including obliterative lesions, inflammation, increased cell turnover, and ongoing apoptosis, represent a final common pathway of a disease that can evolve as a consequence of a variety of insults to the lung vasculature.


Assuntos
Hipertensão Pulmonar/patologia , Animais , Pressão Sanguínea , Modelos Animais de Doenças , Hipertensão Pulmonar/etiologia , Indóis , Masculino , Pneumonectomia , Pirróis , Ratos Sprague-Dawley
2.
Vascul Pharmacol ; 83: 17-25, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-26804008

RESUMO

In pulmonary arterial hypertension (PAH) structural and functional abnormalities of the small lung vessels interact and lead to a progressive increase in pulmonary vascular resistance and right heart failure. A current pathobiological concept characterizes PAH as a 'quasi-malignant' disease focusing on cancer-like alterations in endothelial cells (EC) and the importance of their acquired apoptosis-resistant, hyper-proliferative phenotype in the process of vascular remodeling. While changes in pulmonary blood flow (PBF) have been long-since recognized and linked to the development of PAH, little is known about a possible relationship between an altered PBF and the quasi-malignant cell phenotype in the pulmonary vascular wall. This review summarizes recognized and hypothetical effects of an abnormal PBF on the pulmonary vascular bed and links these to quasi-malignant changes found in the pulmonary endothelium. Here we describe that abnormal PBF does not only trigger a pulmonary vascular cell growth program, but may also maintain the cancer-like phenotype of the endothelium. Consequently, normalization of PBF and EC response to abnormal PBF may represent a treatment strategy in patients with established PAH.


Assuntos
Células Endoteliais/patologia , Hipertensão Pulmonar/patologia , Hipertensão Pulmonar/fisiopatologia , Neoplasias/patologia , Artéria Pulmonar/patologia , Artéria Pulmonar/fisiopatologia , Circulação Pulmonar , Proteínas Angiogênicas/metabolismo , Animais , Apoptose , Proliferação de Células , Células Endoteliais/metabolismo , Metabolismo Energético , Humanos , Hipertensão Pulmonar/metabolismo , Mecanotransdução Celular , Neoplasias/metabolismo , Neovascularização Patológica , Fenótipo , Artéria Pulmonar/metabolismo , Fluxo Sanguíneo Regional , Estresse Mecânico
4.
Eur Respir J ; 37(4): 775-83, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20562128

RESUMO

The pathobiology of chronic obstructive pulmonary disease (COPD) is not completely understood. The aim of this study was to assess the expression of hypoxia inducible factor (HIF)-1α in lung tissue from patients with COPD/emphysema. Lung tissue samples from 26 patients were included in this study. Seven samples were obtained from patients with normal lung function, the remainder of the samples were taken from patients with moderate COPD (n = 6; stage I and II Global Initiative for Chronic Obstructive Lung Disease classification) and severe COPD (n = 13; stage III and IV). We analysed mRNA and protein expression in the lung tissue samples and found that: 1) HIF-1α and histone deacetylase 2 proteins were significantly decreased and were correlated; 2) HIF-1α and vascular endothelial growth factor (VEGF) proteins, and forced expiratory volume in 1 s % predicted were correlated in all patients; 3) the changes in VEGF and HIF-1α protein levels in all patients were not age-related and not related to the pack-yr smoking history; and 4) the reduced HIF-1α protein expression was seen in lung endothelial cells and alveolar septal cells by immunohistochemistry. In conclusion, reduced expression of HIF-1α protein in severe COPD is consistent with the concept of a lung structure maintenance programme which is impaired on a molecular level.


Assuntos
Enfisema/metabolismo , Regulação da Expressão Gênica , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Pulmão/metabolismo , Doença Pulmonar Obstrutiva Crônica/metabolismo , Idoso , Núcleo Celular/metabolismo , Estudos de Coortes , Citoplasma/metabolismo , Feminino , Perfilação da Expressão Gênica , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Fator A de Crescimento do Endotélio Vascular/metabolismo
5.
Eur Respir J ; 35(4): 904-12, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19897563

RESUMO

We hypothesised that endothelin (ET)-1 plays an important role in the pathogenesis of emphysema. We attempted to apply ET-1 receptor antagonists to demonstrate and further elucidate the molecular pathogenesis pathways through which ET-1 may cause emphysematous changes. Sprague-Dawley rats were divided into four groups: control, cigarette smoke extract (CSE), CSE+BQ-123 (a selective endothelin receptor type A (ET(A)) antagonist) and CSE+bosentan (a mixed ET(A)/ET(B) receptor antagonist). The CSE was injected intraperitoneally once a week for 3 weeks, and BQ-123 or bosentan was administered daily for the same duration. The expression of ET(A) receptor, apoptosis index, caspase-3 activity, matrix metalloproteinase (MMP)-2 and MMP-9 activity, and tumour necrosis factor (TNF)-alpha and interleukin (IL)-1beta concentrations were measured in the lung tissue. The ET-1 levels and antioxidant activity were measured in the serum. Both BQ-123 and bosentan prevented the development of CSE-induced emphysema, blocked the expression of ET(A) receptor, inhibited pulmonary apoptosis, inactivated MMP-2 and MMP-9 activities in the lung tissues, reduced the concentrations of inflammatory cytokines TNF-alpha and IL-1beta, and improved the biological antioxidant activity in the serum. Emphysema development is suppressed by ET-1 receptor antagonists. ET-1 may cause emphysematous changes through molecular pathogenesis pathways involving apoptosis, proteinase and antiproteinase imbalance, inflammation and oxidative stress.


Assuntos
Antagonistas do Receptor de Endotelina A , Peptídeos Cíclicos/farmacologia , Enfisema Pulmonar/tratamento farmacológico , Enfisema Pulmonar/prevenção & controle , Sulfonamidas/farmacologia , Animais , Anti-Hipertensivos/farmacologia , Western Blotting , Bosentana , Caspase 3/metabolismo , Endotelina-1/sangue , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Injeções Intraperitoneais , Pulmão/efeitos dos fármacos , Pulmão/patologia , Masculino , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Enfisema Pulmonar/patologia , Ratos , Ratos Sprague-Dawley , Receptor de Endotelina A/metabolismo , Fumar/efeitos adversos
6.
Eur Respir J ; 33(5): 1031-8, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19129289

RESUMO

Self-management strategies improve a variety of health-related outcomes for patients with chronic obstructive pulmonary disease (COPD). These strategies, however, are primarily designed to improve chronic disease management and have not focused on early detection and early treatment of exacerbations. In COPD, the majority of exacerbations go unreported and treatment is frequently delayed, resulting in worsened outcomes. Therefore, a randomised clinical trial was designed to determine whether integration of self-management education with proactive remote disease monitoring would improve health-related outcomes. A total of 40 Global Initiative for Chronic Obstructive Lung Disease stage 3 or 4 COPD patients were randomised to receive proactive integrated care (PIC) or usual care (UC) over a 3-month period. The primary and secondary outcomes were change in quality of life, measured by the St George's Respiratory Questionnaire (SGRQ), and change in healthcare costs. PIC dramatically improved SGRQ by 10.3 units, compared to 0.6 units in the UC group. Healthcare costs declined in the PIC group by US$1,401, compared with an increase of US$1,709 in the UC group, but this was not statistically significant. PIC uncovered nine exacerbations, seven of which were unreported. Therefore, proactive integrated care has the potential to improve outcomes in chronic obstructive pulmonary disease patients through effects of self-management, as well as early detection and treatment of exacerbations.


Assuntos
Prestação Integrada de Cuidados de Saúde/métodos , Doença Pulmonar Obstrutiva Crônica/terapia , Qualidade de Vida , Autocuidado , Idoso , Prestação Integrada de Cuidados de Saúde/economia , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Educação de Pacientes como Assunto/economia , Satisfação do Paciente , Doença Pulmonar Obstrutiva Crônica/economia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Fatores de Risco , Estatísticas não Paramétricas , Inquéritos e Questionários , Telefone , Resultado do Tratamento
7.
Curr Drug Targets ; 7(6): 737-41, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16787175

RESUMO

Pulmonary emphysema, a major component of chronic obstructive pulmonary diseases, is a highly prevalent progressive tissue-destructive disease, with no effective treatments. The interplay between inflammation, matrix proteolysis, oxidative stress and apoptosis might account for the irreversible progression of the disease. Recent investigations have underlined the importance of the lung vasculature in the pathobiology of chronic obstructive pulmonary diseases offering new therapeutic strategies. This review will focus on the pulmonary microvessels as a target in the treatment of pulmonary emphysema.


Assuntos
Pulmão/irrigação sanguínea , Enfisema Pulmonar , Animais , Apoptose/efeitos dos fármacos , Capilares/efeitos dos fármacos , Capilares/imunologia , Capilares/patologia , Humanos , Pulmão/imunologia , Pulmão/patologia , Estresse Oxidativo/efeitos dos fármacos , Enfisema Pulmonar/imunologia , Enfisema Pulmonar/patologia , Enfisema Pulmonar/terapia , Medicamentos para o Sistema Respiratório/uso terapêutico
8.
Eur Respir J ; 26(6): 1110-8, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16319344

RESUMO

The association between autoimmunity and pulmonary arterial hypertension (PAH) has been appreciated for >40 yrs, but how autoimmune injury might contribute to the pathogenesis of this disease has only been examined in a case-specific manner. It is becoming increasingly clear that a variety of diverse clinical diseases, ranging from viral infections to connective tissue disorders, can culminate in pulmonary vascular pathology that is indistinguishable. Is there a hitherto unappreciated biology that unites these seemingly unrelated conditions? The answer to this question may come from the increasing body of evidence concerned with the central importance of regulatory T-cells in preventing inappropriate B-cell activity. Two striking similarities between conditions associated with severe angioproliferative pulmonary hypertension are a defect in the CD4 T-cell compartment and auto-antibody production. Pathogenic auto-antibodies targeting endothelial cells are capable of inducing vascular endothelial apoptosis and may initiate the development of PAH. The present review will focus on what is known about autoimmune phenomena in pulmonary arterial hypertension patients, in order to better consider whether an early loss of self-tolerance followed by autoimmune injury could influence the early development of severe angioproliferative pulmonary hypertension.


Assuntos
Doenças Autoimunes/epidemiologia , Autoimunidade/imunologia , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/patologia , Adulto , Distribuição por Idade , Idoso , Doenças Autoimunes/diagnóstico , Biópsia por Agulha , Comorbidade , Feminino , Humanos , Hipertensão Pulmonar/imunologia , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Prevalência , Prognóstico , Medição de Risco , Índice de Gravidade de Doença , Distribuição por Sexo , Análise de Sobrevida
10.
Eur Respir J Suppl ; 46: 28s-32s, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14621104

RESUMO

Chronic obstructive lung disease affects the entire lung, not just the airways. Although pulmonary hypertension (PH) has long been recognised in a subset of patients with COLD, the important pathophysiological questions remain unanswered. Oxygen supplementation, however, has been shown to blunt the exercise-induced PH in these patients. Hypercoagulability has also been described in patients with COLD. This may, in part, be due to the inflammatory aspects of COLD exacerbation events. In addition to perivascular inflammation, the pathology of vessels in COLD includes intimal thickening, muscularisation of arterioles, in situ thrombosis, loss of capillaries and precapillary arterioles, and vascular congestion and stasis. Recent work describes apoptosis of septal endothelial cells and decreased expression of vascular endothelial growth factor (VEGF) and one of its receptors, VEGFRII, in lungs from patients with emphysema. Based on this work, a rat model was developed that shows chronic blockade of VEGF receptors leads to septal cell apoptosis and results in emphysema and PH. This animal model has led to prevention trials using 1) a broad-spectrum caspase inhibitor, 2) a superoxide dismutase mimetic, and 3) alpha1-antitrypsin. These findings highlight the importance of vascular endothelial growth factor, apoptosis, oxidative stress and protease activity in the pathogenesis of emphysema. They also underscore the importance of the vasculature in what is traditionally thought of as an airways disease. Future treatment strategies need to address the vascular components of chronic obstructive lung disease.


Assuntos
Artéria Pulmonar/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Animais , Coagulação Sanguínea , Endotélio Vascular/fisiopatologia , Humanos , Hipertensão/patologia , Hipertensão/fisiopatologia , Inflamação , Artéria Pulmonar/patologia , Doença Pulmonar Obstrutiva Crônica/sangue , Doença Pulmonar Obstrutiva Crônica/complicações , Doença Pulmonar Obstrutiva Crônica/patologia , Enfisema Pulmonar/patologia , Enfisema Pulmonar/fisiopatologia , Receptores de Fatores de Crescimento do Endotélio Vascular/fisiologia , Trombose/etiologia , Trombose/fisiopatologia
11.
Eur Respir J ; 22(3): 403-7, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14516126

RESUMO

Primary pulmonary hypertension (PPH) and Castleman's disease (CD) are rare conditions infrequently encountered in clinical practice. In this paper, two patients diagnosed with both of these diseases are reported. The authors speculate that rather than being a chance occurrence, these conditions are linked by a common angio-proliferative mechanism. Therefore, an association between infection with the human herpesvirus-8 and the diseases of PPH and CD was sought. Evidence of human herpesvirus-8 infection was found in the lung tissue and, specifically, in the plexiform lesions from one of the patients.


Assuntos
Hiperplasia do Linfonodo Gigante/virologia , Infecções por Herpesviridae/complicações , Herpesvirus Humano 8/isolamento & purificação , Hipertensão Pulmonar/virologia , Adulto , Cateterismo Cardíaco , Hiperplasia do Linfonodo Gigante/patologia , Feminino , Infecções por Herpesviridae/patologia , Humanos , Hipertensão Pulmonar/patologia , Imuno-Histoquímica , Pulmão/patologia , Linfonodos/patologia , Masculino , Reação em Cadeia da Polimerase
12.
Respir Res ; 2(4): 210-5, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11686886

RESUMO

Genomics, or the study of genes and their function, is a burgeoning field with many new technologies. In the present review, we explore the application of genomic approaches to the study of pulmonary hypertension (PH). Candidate genes, important to the pathobiology of the disease, have been investigated. Rodent models enable the manipulation of selected genes, either by transgenesis or targeted disruption. Mutational analysis of genes in the transforming growth factor-beta family have proven pivotal in both familial and sporadic forms of primary PH. Finally, microarray gene expression analysis is a robust molecular tool to aid in delineating the pathobiology of this disease.


Assuntos
Hipertensão Pulmonar/genética , Animais , Modelos Animais de Doenças , Humanos , Camundongos , Camundongos Transgênicos , Mutação , Análise de Sequência com Séries de Oligonucleotídeos
13.
J Pathol ; 195(3): 367-74, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11673836

RESUMO

Pulmonary arteries of patients with severe pulmonary hypertension (SPH) presenting in an idiopathic form (primary PH-PPH) or associated with congenital heart malformations or collagen vascular diseases show plexiform lesions. It is postulated that in lungs with SPH, endothelial cells in plexiform lesions express genes encoding for proteins involved in angiogenesis, in particular, vascular endothelial growth factor (VEGF) and those involved in VEGF receptor-2 (VEGFR-2) signalling. On immunohistochemistry and in situ hybridization, endothelial cells in the plexiform lesions expressed VEGF mRNA and protein and overexpressed the mRNA and protein of VEGFR-2, and the transcription factor subunits HIF-1alpha and HIF-1beta of hypoxia inducible factor, which are responsible for the hypoxia-dependent induction of VEGF. When compared with normal lungs, SPH lungs showed decreased expression of the kinases PI3 kinase and src, which, together with Akt, relay the signal transduction downstream of VEGFR-2. Because markers of angiogenesis are expressed in plexiform lesions in SPH, it is proposed that these lesions may form by a process of disordered angiogenesis.


Assuntos
Proteínas de Ligação a DNA , Fatores de Crescimento Endotelial/análise , Hipertensão Pulmonar/metabolismo , Linfocinas/análise , Artéria Pulmonar/metabolismo , Receptores Proteína Tirosina Quinases/análise , Receptores de Hidrocarboneto Arílico , Receptores de Fatores de Crescimento/análise , Translocador Nuclear Receptor Aril Hidrocarboneto , Biomarcadores/análise , Estudos de Casos e Controles , Fatores de Crescimento Endotelial/genética , Humanos , Hipertensão Pulmonar/patologia , Subunidade alfa do Fator 1 Induzível por Hipóxia , Hibridização In Situ/métodos , Linfocinas/genética , Neovascularização Patológica , Oligopeptídeos/análise , Fosfatidilinositol 3-Quinases/análise , Artéria Pulmonar/patologia , RNA Mensageiro/análise , Receptores Proteína Tirosina Quinases/genética , Receptores de Fatores de Crescimento/genética , Receptores de Fatores de Crescimento do Endotélio Vascular , Fatores de Transcrição/análise , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
14.
Clin Chest Med ; 22(3): 405-18, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11590837

RESUMO

Dysfunctional endothelial cells have a central and critical role in the initiation and progression of severe pulmonary hypertension. The elucidation of the mechanisms involved in the control of endothelial cell proliferation and cell death in the pulmonary vasculature, therefore, is fundamentally important in the pathogenesis of severe pulmonary hypertension and of great interest for a better understanding of endothelial cell biology. Because the intravascular growth of endothelial cells resulting in tumorlets is unique to severe pulmonary hypertension, this phenomenon can teach researchers about the factors involved in the formation and maintenance of the normal endothelial cell monolayer. Clearly, in severe pulmonary hypertension, the "law of the endothelial cell monolayer" has been broken. The ultimate level of such a control is at the altered gene expression pattern that is conducive to endothelial cell growth and disruption of pulmonary blood flow. Secondary pulmonary hypertension certainly also is associated with proliferated pulmonary endothelial cells and plexiform lesions that are histologically indistinguishable from those in PPH. What is then the difference in the mechanisms of endothelial cell proliferation between primary and secondary pulmonary hypertension? The authors believe that PPH is a disease caused by somatic mutations in key angiogenesis- or apoptosis-related genes such as the TGF-beta receptor-2 and Bax. The loss of these important cell growth control mechanisms allows for the clonal expansion of endothelial cells from a single cell that has acquired a selective growth advantage. On the other hand, the proliferated endothelial cells in secondary pulmonary hypertension are polyclonal. It follows from this finding that local (vascular) factor(s) (such as increased shear stress), rather than mutations, play a major role in triggering endothelial cell proliferation. In PPH and secondary pulmonary hypertension, the researcher can postulate that the pulmonary vascular bed contains progenitor-like cells with the capacity of dysregulated growth. The main difference in the pathogenesis of primary and secondary pulmonary endothelial cell proliferation therefore may be the initial mechanism involved in the recruitment of an endothelial progenitor-like cell. In PPH, anorexigen-associated, and familial PPH, the proliferation of endothelial cells occurs from a mutated single cell, whereas in secondary pulmonary hypertension, several progenitor-like cells would be activated to grow. The abnormal endothelial cells in both forms of severe pulmonary hypertension expand because of the expression of angiogenesis-related molecules such as VEGF, VEGFR-2, HIF-1 alpha, and HIF-beta. Also important for the expansion of these cells is the down-regulation of expression of apoptosis-related mediators such as TGF-beta receptor-2 or Bax. The success of any therapy for severe pulmonary hypertension requires that the underlying process of endothelial cell proliferation could be controlled or reversed.


Assuntos
Endotélio Vascular/fisiopatologia , Hipertensão Pulmonar/fisiopatologia , Animais , Coagulação Sanguínea/fisiologia , Sistema Enzimático do Citocromo P-450/metabolismo , Fatores de Crescimento Endotelial/metabolismo , Endotélio Vascular/patologia , Humanos , Hipertensão Pulmonar/genética , Hipertensão Pulmonar/patologia , Oxirredutases Intramoleculares/metabolismo , Linfocinas/metabolismo , Repetições de Microssatélites , Músculo Liso Vascular/patologia , Músculo Liso Vascular/fisiopatologia , Mutação , Óxido Nítrico/metabolismo , Isoformas de Proteínas/metabolismo , Artéria Pulmonar/patologia , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular , Vasoconstrição
15.
Eur Respir J ; 17(6): 1065-9, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11491145

RESUMO

The recent discoveries of the familial primary pulmonary hypertension gene and somatic mutations in key cell growth and cell death regulatory genes in primary pulmonary hypertension have added a new dimension to severe pulmonary hypertension research. These findings have already impacted on how the disease is viewed, and ultimately, how severe pulmonary hypertension is diagnosed and treated. However, this new information raises several fundamental questions related to the role of bone morphogenetic protein receptor signalling in the control of lung vascular cell function. Furthermore, additional genes and gene products may also be involved in the pathogenesis of the disease. The way severe pulmonary hypertension is viewed and studied is on the verge of shifting from a vasoconstrictive to a cell growth paradigm.


Assuntos
Hipertensão Pulmonar/genética , Receptores de Proteínas Morfogenéticas Ósseas Tipo II , Análise Mutacional de DNA , Endotélio Vascular/fisiopatologia , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/fisiopatologia , Proteínas Serina-Treonina Quinases/genética , Receptor do Fator de Crescimento Transformador beta Tipo II , Receptores de Fatores de Crescimento Transformadores beta/genética , Transdução de Sinais/fisiologia
17.
Am J Respir Crit Care Med ; 164(2): 314-8, 2001 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-11463607

RESUMO

Prostacyclin (PGI(2)) reduces pulmonary vascular resistance and attenuates vascular smooth muscle cell proliferation through signal transduction following ligand binding to its receptor. Because patients with severe pulmonary hypertension have a reduced PGI(2) receptor (PGI-R) expression in the remodeled pulmonary arterial smooth muscle, we hypothesized that pulmonary vascular remodeling may be modified PGI-R dependently. To test this hypothesis, PGI-R knockout (KO) and wild-type (WT) mice were subjected to a simulated altitude of 17,000 ft or Denver altitude for 3 wk, and right ventricular pressure and lung histology were assessed. The PGI-R KO mice developed more severe pulmonary hypertension and vascular remodeling after chronic hypoxic exposure when compared to the WT mice. Our results indicate that PGI(2) and its receptor play an important role in the regulation of hypoxia-induced pulmonary vascular remodeling, and that the absence of a functional receptor worsens pulmonary hypertension.


Assuntos
Artéria Pulmonar/fisiologia , Receptores de Prostaglandina/fisiologia , Animais , Camundongos , Camundongos Knockout , Receptores de Epoprostenol
18.
Circ Res ; 88(6): 555-62, 2001 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-11282888

RESUMO

Primary pulmonary hypertension (PPH) is a disease of unknown etiology characterized by lumen-obliterating endothelial cell proliferation and vascular smooth muscle hypertrophy of the small precapillary pulmonary arteries. Because the vascular lesions are homogeneously distributed throughout the entire lung, we propose that a tissue fragment of the lung is representative of the whole lung. RNA extracted from the fragments is likely to provide meaningful information regarding the changes in gene expression pattern in PPH when compared with structurally normal lung tissue. We hypothesize that the lung tissue gene expression pattern of patients with PPH has a characteristic profile when compared with the gene expression pattern of structurally normal lungs and that this characteristic gene expression profile provides new insights into the pathobiology of PPH. Using oligonucleotide microarray technology, we characterized the expression pattern in the lung tissue obtained from 6 patients with primary pulmonary hypertension (PPH)-including 2 patients with the familial form of PPH (FPPH)-and from 6 patients with histologically normal lungs. For the data analysis, gene clusters were generated and the gene expression pattern differences between PPH and normal lung tissue and between PPH and FPPH lung tissue were compared. All PPH lung tissue samples showed a decreased expression of genes encoding several kinases and phosphatases, whereas several oncogenes and genes coding for ion channel proteins were upregulated in their expression. Importantly, we could distinguish by pattern comparison between sporadic PPH and FPPH, because alterations in the expression of transforming growth factor-beta receptor III, bone morphogenic protein 2, mitogen-activated protein kinase kinase 5, RACK 1, apolipoprotein C-III, and the gene encoding the laminin receptor 1 were only found in the samples from patients with sporadic PPH, but not in FPPH samples. We conclude that the microarray gene expression technique is a new and useful molecular tool that provides novel information pertinent to a better characterization and understanding of the pathobiology of the distinct clinical phenotypes of pulmonary hypertension.


Assuntos
Perfilação da Expressão Gênica , Hipertensão Pulmonar/genética , Pulmão/metabolismo , Adulto , Feminino , Humanos , Pulmão/patologia , Masculino , Pessoa de Meia-Idade , Análise de Sequência com Séries de Oligonucleotídeos , RNA/genética , RNA/metabolismo
19.
Am J Respir Crit Care Med ; 163(3 Pt 1): 737-44, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11254533

RESUMO

Emphysema due to cigarette smoking is characterized by a loss of alveolar structures. We hypothesize that the disappearance of alveoli involves apoptosis of septal endothelial cells and a decreased expression of lung vascular endothelial growth factor (VEGF) and its receptor 2 (VEGF R2). By terminal transferase dUTP nick end labeling (TUNEL) in combination with immunohistochemistry, we found that the number of TUNEL+ septal epithelial and endothelial cells/lung tissue nucleic acid (microg) was increased in the alveolar septa of emphysema lungs (14.2 +/- 2.0/microg, n = 6) when compared with normal lungs (6.8 +/- 1.3/microg, n = 7) (p < 0.01) and with primary pulmonary hypertensive lungs (2.3 +/- 0.8/microg, n = 5) (p < 0.001). The cell death events were not significantly different between healthy nonsmoker (7.4 +/- 1.9/microg) and smoker (5.7 +/- 0.7/microg) control subjects. The TUNEL results were confirmed by single-stranded DNA and active caspase-3 immunohistochemistry, and by DNA ligation assay. Emphysema lungs (n = 12) had increased levels of oligonucleosomal-length DNA fragmentation when compared with normal lungs (n = 11). VEGF, VEGF R2 protein, and mRNA expression were significantly reduced in emphysema. We propose that epithelial and endothelial alveolar septal death due to a decrease of endothelial cell maintenance factors may be part of the pathogenesis of emphysema.


Assuntos
Apoptose , Enfisema/metabolismo , Enfisema/patologia , Fatores de Crescimento Endotelial/biossíntese , Receptores ErbB/biossíntese , Linfocinas/biossíntese , Adolescente , Adulto , Idoso , Enfisema/genética , Fatores de Crescimento Endotelial/análise , Receptores ErbB/análise , Feminino , Humanos , Marcação In Situ das Extremidades Cortadas , Linfocinas/análise , Masculino , Pessoa de Meia-Idade , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
20.
J Appl Physiol (1985) ; 90(4): 1299-306, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11247927

RESUMO

Chronic hypoxia causes pulmonary hypertension and right ventricular hypertrophy associated with pulmonary vascular remodeling. Because hypoxia might promote generation of oxidative stress in vivo, we hypothesized that oxidative stress may play a role in the hypoxia-induced cardiopulmonary changes and examined the effect of treatment with the antioxidant N-acetylcysteine (NAC) in rats. NAC reduced hypoxia-induced cardiopulmonary alterations at 3 wk of hypoxia. Lung phosphatidylcholine hydroperoxide (PCOOH) increased at days 1 and 7 of the hypoxic exposure, and NAC attenuated the increase in lung PCOOH. Lung xanthine oxidase (XO) activity was elevated from day 1 through day 21, especially during the initial 3 days of the hypoxic exposure. The XO inhibitor allopurinol significantly inhibited the hypoxia-induced increase in lung PCOOH and pulmonary hypertension, and allopurinol treatment only for the initial 3 days also reduced the hypoxia-induced right ventricular hypertrophy and pulmonary vascular thickening. These results suggest that oxidative stress produced by activated XO in the induction phase of hypoxic exposure contributes to the development of chronic hypoxic pulmonary hypertension.


Assuntos
Hipertensão Pulmonar/metabolismo , Estresse Oxidativo , Oxigênio/farmacologia , Acetilcisteína/farmacologia , Alopurinol/farmacologia , Animais , Antioxidantes/farmacologia , Doença Crônica , Inibidores Enzimáticos/farmacologia , Hipertensão Pulmonar/patologia , Hipertensão Pulmonar/fisiopatologia , Hipertrofia Ventricular Direita/patologia , Hipertrofia Ventricular Direita/fisiopatologia , Pulmão/metabolismo , Masculino , Oxigênio/metabolismo , Fosfatidilcolinas/metabolismo , Artéria Pulmonar/patologia , Ratos , Ratos Sprague-Dawley , Túnica Média/patologia , Função Ventricular Direita , Xantina Oxidase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...